ARTICLE | Company News
GlaxoSmithKline, Competition and Markets Authority neurology, generics news
February 22, 2016 8:00 AM UTC
CMA imposed L45 million ($64.8 million) in fines for “pay-for-delay” conduct and agreements occurring between 2001-04 during which GlaxoSmithKline paid over L50 million ($72 million) to suppliers of g...